Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Influenza | Correction

Correction to: Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade

Authors: Seyed Mohammad Miri, Mir Saeed Ebrahimzadeh, Elahe Abdolalipour, Mahsa Yazdi, Hassan Hosseini Ravandi, Amir Ghaemi

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Excerpt

Following publication of the original article [1], we were notified the Department of Virology, Pasteur Institute of Iran should have been mentioned as the only affiliation for the first, third and last author. The revised affiliation is reflected in this correction article. …
Literature
1.
Metadata
Title
Correction to: Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
Authors
Seyed Mohammad Miri
Mir Saeed Ebrahimzadeh
Elahe Abdolalipour
Mahsa Yazdi
Hassan Hosseini Ravandi
Amir Ghaemi
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Influenza
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01610-3

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

A novel role of Krüppel-like factor 8 as an apoptosis repressor in hepatocellular carcinoma

Primary research

Identification of metabolism-associated genes and construction of a prognostic signature in bladder cancer

Primary research

Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo

Primary research

ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments

Primary research

FBXO2 modulates STAT3 signaling to regulate proliferation and tumorigenicity of osteosarcoma cells

Primary research

Cyclin H predicts the poor prognosis and promotes the proliferation of ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits